非小细胞肺癌靶向药物rociletinib相关研究进展

doi:10.3969/j.issn.1671-7171.2017.04.032

摘要
图/表
参考文献
相关文章 (15)

[1] Sharma SV, Bell DW, Settleman J,et al. Epidermal growth factor receptor mutations in lung cancer[J].Nat Rev Cancer,2007, 7(3):169-181.
[2] Eck MJ, Yun CH. Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer[J].Biochim Biophys Acta,2010, 1804(3): 559-566.
[3] Stamos J, Sliwkowski M X, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor[J].J Biol Chem,2002, 277(48): 46265-46272.
[4] Ning J, Wu Q, Liu Z, et al. Mapping inhibitor response to the in-frame deletions, insertions and duplications of epidermal growth factor receptor (EGFR) in non-small cell lung cancer[J].J Recept Signal Transduct Res,2016, 36(1):37-44.
[5] Wu JY, Wu SG, Yang CH, et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response[J].Clin Cancer Res,2008, 14(15):4877-4882.
[6] Cho J, Chen L, Sangji N, et al. Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization[J].Cancer Res,2013, 73(22): 6770-6779.
[7] Walter AO, Sjin RT, Haringsma HJ, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC[J].Cancer Discov,2013,3(12):1404-1415.
[8] Piotrowska Z, Niederst MJ, Karlovich CA, et al. Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor[J].Cancer Discov,2015, 5(7):713-722.
[9] Dhingra K. Rociletinib: has the TIGER lost a few of its stripes[J].Ann Oncol,2016, 27(6):1161-1164.
[10] Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer[J].N Engl J Med,2015, 372(18):1700-1709.
[11] Simmons AD, Jaw-Tsai S, Haringsma HJ, et al. Abstract 793: Insulin-like growth factor 1 (IGF1R)/insulin receptor (INSR) inhibitory activity of rociletinib (CO-1686) and its metabolites in nonclinical models[J].Cancer Research,2015, 75( Suppl 15):793.
[12] Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[J].Cancer Discov,2014,4(9):1046-1061.
[13] Galvani E, Sun J, Leon L G, et al. NF-kappaB drives acquired resistance to a novel mutant-selective EGFR inhibitor[J].Oncotarget,2015, 6(40): 42717-42732.
[14] Ercan D, Choi HG, Yun CH, et al. EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors[J].Clin Cancer Res,2015, 21(17):3913-3923.
[15] Niederst MJ, Sequist LV, Poirier JT, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer[J].Nat Commun,2015, 6:6377.
[16] Sequist LV, Piotrowska Z, Niederst MJ, et al. Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib[J].JAMA Oncol,2016,2(4):541-543.
[17] Sequist LV, Goldman JW, Wakelee HA, et al. Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts)[C].ASCO Annual Meeting,2015.
[18] Goldman JW, Soria J-C, Wakelee HA, et al. Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC)[J].J Clin Oncol,2016,34(Suppl 15):abstract 9045.
[19] Clovis Oncology, Inc. TIGER-2: A Phase 2, Open-label, Multicenter,Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell Lung Cancer(NSCLC).NCT02147990.Boulder,CO,USA:Clovis Oncology,Inc.
[20] Clovis Oncology, Inc. TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinumdoublet Chemothera. NCT02322281. Boulder,CO,USA:Clovis Oncology, Inc.
[21] Clovis Oncology, Inc. TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy.NCT02186301. Boulder, CO, USA: Clovis Oncology, Inc.
[22] Jnne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer[J].N Engl J Med,2015,372(18):1689-1699.
[23] Dickinson PA, Cantarini MV, Collier J, et al. Metabolic disposition of osimertinib in rat, dog, and man: insights into a drug designed to bind covalently to a cysteine residue of EGFR[J].Drug Metab Dispos,2016, 44(8):1201-1212.
[24] Ballard P, Yates JW, Yang Z, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity[J].Clin Cancer Res,2016,19.
[25] Ahn MJ, Tsai CM, Yang JC, et al. AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: data from Phase II studies[J].Eur J Cancer,2015,51(Suppl 3):S625-S626.
(本文编辑:詹道友) [收稿日期] 2017-02-26